Drug Profile
Research programme: radiolabelled edotreotide - Progenics Pharmaceuticals
Alternative Names: DOTA-Tyr3-octreotide - Progenics Pharmaceuticals; Edotreotide - Progenics Pharmaceuticals; Radiolabelled DOTA-TOC - Progenics PharmaceuticalsLatest Information Update: 19 Jun 2020
Price :
$50
*
At a glance
- Originator Unknown
- Developer ITM Group; Progenics Pharmaceuticals
- Class Cyclic peptides; Organotechnetium compounds; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Somatostatin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Neuroendocrine tumours
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 18 Sep 2013 Edotreotide and certain radiolabelled edotreotide products sublicensed to itm Group worldwide (excluding Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi Arabia, Syria, Turkey and United Arab Emirates)
- 18 Sep 2013 Investigation in Neuroendocrine tumours in Germany (IV)